Reversibility of Trastuzumab Cardiotoxicity: Is the Concept Alive and Well?
Authors:
- 1 December 2007
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (34) , 5532-5533
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- The anthracycline-trastuzumab interaction: Up-regulated binding may provide vital mechanistic insightEuropean Journal of Cancer, 2007
- Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant TrialJournal of Clinical Oncology, 2007
- 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicityEuropean Journal of Cancer, 2007
- Trastuzumab-Related Cardiotoxicity: Calling Into Question the Concept of ReversibilityJournal of Clinical Oncology, 2007
- Long-Term Cardiac Tolerability of Trastuzumab in Metastatic Breast Cancer: The M.D. Anderson Cancer Center ExperienceJournal of Clinical Oncology, 2006
- Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical TreatmentJournal of Clinical Oncology, 2005
- Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31Journal of Clinical Oncology, 2005
- Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New EntityJournal of Clinical Oncology, 2005